Pediatric research
October 8, 2026 · via Europe PMC
The potential role of miR-34a and miR-34c in the regulation of pediatric high-grade glioma 4 aggressiveness.
Rogachevsky D, Yalon M, Mehrian-Shai R, Toren A.
AI summary — for doctors, generated from the abstract only
Restoring miR-34a and miR-34c reduced aggressive behavior in pediatric high-grade glioma cell models, suggesting a possible therapeutic avenue.
What was studied
A laboratory study of miR-34a and miR-34c levels in pediatric high-grade glioma grade 4 cell lines and tumor datasets, with mimic transfection in SF188 and KNS42 cells to test viability, migration, invasiveness and related gene expression.
Key findings
- miR-34a and miR-34c were scarcely expressed in cell lines, and miR-34c was downregulated in tumor datasets
- Raising their levels decreased cell viability, migration and invasiveness
- Effects on survival, cell-cycle, apoptosis and EMT genes differed by miRNA and cell line
Clinical relevance
The work supports further exploration of miR-34-based strategies for a currently incurable tumor, but it is far from patient use.
Who should care
Limitations
Cell-line and dataset work only, with no animal or patient testing and no quantitative effect sizes in the abstract; the claim that these miRNAs are powerful therapeutic tools is stronger than the evidence.
miR-34a and miR-34c behaved as tumor suppressors in glioma cells, an early-stage finding.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Background
Pediatric diffuse high-grade gliomas grade 4 (pHGG-4), the most aggressive malignant primary brain tumors, are incurable and associated with poor prognosis. In most pHGG-4, meaningful genetic aberrations were rarely found, and the aggressiveness is derived from epigenetic changes and dysregulated gene expression. miRNAs are significant epigenetic regulators of gene expression that play important roles in many cancers.
Methods
miR-34a and miR-34c levels were analyzed in pHGG cell lines and tumor datasets. SF188 and KNS42 cells were transfected with miR-34a/miR-34c mimic or scrambled oligonucleotide, and examined for viability, migration ability, and invasiveness. Expression of survival, cell cycle arrest/progression, apoptosis, and Epithelial-Mesenchymal Transition (EMT) regulating genes was examined using quantitative PCR (qPCR), western blot, and immunofluorescence assays.
Results
miR-34a and miR-34c were scarcely expressed in pHGG-4 cell lines, and miR-34c was downregulated in pHGG-4 tumor datasets. Upregulating miR-34a/miR-34c decreased cell viability, migration ability, and invasiveness, while differentially affecting the expression of genes involved in survival, cell progression, proliferation, cell cycle arrest or death, and EMT promotion, depending on the miRNA and cell line.
Conclusions
miR-34a and miR-34c are multifunctional tumor suppressors that play an important regulatory role in pHGG-4 aggressiveness. Both miRNAs can serve as excellent and powerful therapeutic tools against pHGG-4.
Impact
This study revealed miR-34a and miR-34c as multifunctional suppressors of pHGG-4 tumor aggressiveness, both downregulated in disease models. miR-34a/miR-34c restoration decreased cell viability, migration ability, invasiveness, and stemness marker expression Both miRNAs exerted similar phenotypic effects while differentially regulated gene expression in a miRNA-associated and cell line-dependent manner The findings reinforced that epigenetic dysregulation, rather than recurrent genetic alterations, is a central driver of pHGG-4 aggressiveness. This work suggests the rational for potential miR-34-based therapeutic strategies in this otherwise incurable disease.
DOI
10.1038/s41390-026-05518-y
PMID
42850359
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed